Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "DNA Repair Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
As the fight against cancer continues, the importance of DNA repair drugs has surged, with the market experiencing exceptional growth. In 2022, North America led the market contributions. Projections for 2023 estimate an upsurge in the global market, with an expected CAGR of 22%. By 2027, the market is anticipated to reach a valuation of approximately $19 billion, operating at a CAGR of 20.8%.
Surge in Cancer Incidences Fueling Market Expansion
The market analysis covers key drug types like olaparib, rucaparib, and talazoparib, and their applications in treatment facilities, including hospital and retail pharmacies. These drugs are essential in the treatment of various forms of cancer and highlight the market's role in managing genomic integrity in patients.
Recent developments underscore the industry's focus on product innovation and expansion within the genomic therapeutics space. The report features insights into strategic acquisitions and approvals that are set to chart future market dynamics.
- Market Growth Influenced by the Rising Prevalence of Cancer
- Strategic Industry Initiatives and Product Innovation
- Analysis of the Competitive Landscape and Key Players
The documented statistics present an overview of market shares, potential market segments, and major players' positions in the marketplace, offering a comprehensive analysis for stakeholders.
The thorough market evaluation also signifies the impact of global events, such as the Russia-Ukraine conflict, on the market's economy. Despite these challenges, the rising cancer cases globally propound a significant market opportunity, especially with the increased focus on precision medicine and personalized therapies.
The findings indicate an impetus for improvement in cancer treatments and the burgeoning role of DNA repair drugs. It provides stakeholders with crucial data necessary for informed decision-making and strategy formulation in the DNA repair drugs market.
The report encompasses various regional markets, including Asia-Pacific, Europe, North America, South America, the Middle East, and Africa, laying out a geographical analysis imperative for market participants.
This release informs interested readers that a meticulously researched document discussing market size, trends, and opportunities in the DNA repair drugs industry is now accessible, propelling stakeholders toward a future lined with innovation and market preparedness.
A selection of companies mentioned in this report includes
- Pfizer Inc.
- Johnson & Johnson Private Limited
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- GlaxoSmithKline plc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Amgen Inc.
- Merck KGaA
- Regeneron Pharmaceuticals Inc.
- Biogen Inc.
- Vertex Pharmaceuticals Inc.
- Ono Pharmaceutical Co. Ltd.
- Jiangsu HengRui Medicine Co. Ltd.
- BioMarin Pharmaceutical Inc.
- Genentech Inc.
- ClovisOncology Inc.
- Karyopharm Therapeutics Inc.
- Repare Therapeutics Inc.
- Intellia Therapeutics Inc.
- C4 Therapeutics Inc.
- Precision BioSciences
- Artios Pharma Limited
- FoRx Therapeutics AG
- Onxeo SA
- CRISPR Therapeutics AG
For more information about this report visit https://www.researchandmarkets.com/r/8l8z83
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
